Nafamostat Market

Nafamostat Market Size, Share & Industry Analysis, By Source (Pharmaceutical Manufacturers (Branded & Generic), Contract Manufacturing Organizations (CMOs), Research-Grade Suppliers) By End-User (Pharmaceutical Industry, Hospitals & Clinics, Research Institutions) and Forecast, 2025-2035

The Nafamostat market is projected to grow at a CAGR of 8.1% from 2025 to 2035, driven by its increasing use in the treatment of acute pancreatitis, chronic pancreatitis, and COVID-19-related complications. Nafamostat is a serine protease inhibitor that exerts its effects by inhibiting enzymes such as plasminogen activator and trypsin, which play key roles in the inflammatory processes associated with pancreatitis and viral infections.

Nafamostat has gained attention due to its potential therapeutic application in managing viral diseases, particularly as a treatment for COVID-19 due to its ability to inhibit the protease enzyme that the SARS-CoV-2 virus uses to enter human cells. The ongoing exploration of Nafamostat in various clinical trials is expected to expand its use beyond traditional indications, fueling market demand.

Asia-Pacific leads the Nafamostat market, particularly in Japan and South Korea, where the drug is already approved and used in hospital settings for pancreatitis management. Europe is anticipated to experience steady growth, driven by the potential applications of Nafamostat in viral infections and the increasing focus on emergency treatments for acute conditions. North America is also showing rising interest in Nafamostat, especially with its potential in COVID-19 and other viral diseases.

Seeking Comprehensive Intelligence on Different markets? Get in Touch with our Experts

Report Scope & Segmentation

Introduction

Overview of Nafamostat
Key Applications & Industry Use Cases
Market Scope & Study Objectives

Market Overview

Global Market Size & Growth Trends (Historical & Forecast)
Market Value & Revenue Analysis
Demand-Supply Dynamics

Segmental Outlook

By Source
- Pharmaceutical Manufacturers (Branded & Generic)
- Contract Manufacturing Organizations (CMOs)
- Research-Grade Suppliers
Key End-Use Industries
- Pharmaceutical Industry.
- Hospitals & Clinics.
- Research Institutions.

Price Analysis

Current Price Trends (Per kg & Per Ton)
Price Fluctuation Factors (Raw Material Costs, Production, Trade Tariffs)
Regional Price Comparison (North America, Europe, Asia-Pacific, and Other)

Production & Supply Volume

Global Production Capacity & Key Manufacturers
Production Process & Technological Developments
Raw Material Analysis

Trade Analysis (Import & Export)

Major Exporting & Importing Countries
Trade Volume & Value Statistics
Impact of Trade Regulations & Policies

Regional Analysis

North America (US and Canada)
Europe (UK, Germany, France, Italy, Spain, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, Taiwan, India, and Rest of Asia-Pacific)
Rest of the World (Latin America, Middle East, and Africa)

Competitive Landscape

Top Global Manufacturers & Market Share
Company Profiles & Key Developments
Mergers, Acquisitions & Investments

Regulatory & Compliance Factors

FDA, REACH, and Other Regulatory Frameworks
Environmental & Safety Considerations
Emerging Policies Impacting Market Growth

Conclusion & Strategic Recommendations

Key Takeaways for Stakeholders
Market Entry Strategies

May 26, 2025

What is Nafamostat?

Nafamostat is a potent synthetic protease inhibitor primarily used in Japan and South Korea for the treatment of acute pancreatitis and as a part of the management of disseminated intravascular coagulation (DIC). It functions by inhibiting various serine proteases, particularly thrombin and plasmin, which are involved in the clotting process. Nafamostat's ability to block these enzymes prevents the formation of abnormal blood clots and alleviates complications arising from DIC, a condition that can occur in severe infections or trauma. It is also noted for its potential use in preventing the activation of pancreatic enzymes in acute pancreatitis, helping to reduce inflammation and damage to pancreatic tissues. Though primarily available in injection form, Nafamostat is recognized for its rapid onset of action, making it effective in treating these acute conditions.

What is the market growth of Nafamostat?

The global market for Nafamostat is expected to grow at a CAGR of 8.1% from 2025 to 2035. Growth is driven by the increasing prevalence of acute pancreatitis, the need for more effective treatments for DIC, and the rising recognition of Nafamostat's potential role in treating severe inflammatory conditions.

What are the drivers of the Nafamostat market?

Key drivers for the Nafamostat market include the rising incidence of acute pancreatitis and related complications such as DIC, particularly in regions with aging populations. The increasing understanding of Nafamostat’s potential applications in managing severe inflammatory and clotting disorders is also pushing its market growth.

Who are the key players operating in the Nafamostat market?

The key players in the Nafamostat market include Ajinomoto Pharmaceuticals, which manufactures the drug under the brand name Futhan in Japan, and Mitsubishi Tanabe Pharma, which markets it in South Korea. These companies are leaders in the production and distribution of Nafamostat, particularly in Asian markets where the drug is most commonly used.

Which region will exhibit the fastest growth in the Nafamostat market?

The Asia-Pacific region is expected to exhibit the fastest growth in the Nafamostat market, driven by the high prevalence of acute pancreatitis, DIC, and other serious inflammatory conditions in countries like Japan, South Korea, and China.

$1800/- Single User License
$3600/- Multi User License

Experienced in market research and consulting.
Seasoned professionals with diverse industry knowledge.
Proven track record in delivering valuable insights.
Tailored methodologies for unique client needs.
End-to-end services: market analysis, competitor intelligence, consumer behavior, and strategic recommendations.
Latest tools and tech for data collection, analysis, and visualization.
Embrace of AI and machine learning for deeper insights.
Global capabilities and extensive network.
In-depth understanding of international markets, trends, and regulations.
Dedicated to addressing specific client needs and goals.
Focus on delivering value through efficient research outcomes.

How can we help you?

Reach out to discuss how our team can help your business achieve real results.

Contact Person

Mr. Anurag Tiwari

Call Us

+91-780-304-0404

Mail Us

info@omrglobal.com